Resistance from Afar: Distal Mutation V36M Allosterically Modulates the Active Site to Accentuate Drug Resistance in HCV NS3/4A Protease [preprint] by Ozen, Aysegul et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
University of Massachusetts Medical School Faculty Publications 
2018-12-16 
Resistance from Afar: Distal Mutation V36M Allosterically 
Modulates the Active Site to Accentuate Drug Resistance in HCV 
NS3/4A Protease 
Aysegul Ozen 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/faculty_pubs 
 Part of the Biochemistry Commons, Enzymes and Coenzymes Commons, Genetic Phenomena 
Commons, Molecular Biology Commons, Structural Biology Commons, and the Viruses Commons 
Repository Citation 
Ozen A, Lin K, Romano KP, Tavella D, Newton A, Petropoulos CJ, Huang W, Aydin C, Schiffer CA. (2018). 
Resistance from Afar: Distal Mutation V36M Allosterically Modulates the Active Site to Accentuate Drug 
Resistance in HCV NS3/4A Protease. University of Massachusetts Medical School Faculty Publications. 
https://doi.org/10.1101/452284. Retrieved from https://escholarship.umassmed.edu/faculty_pubs/1607 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in University of 
Massachusetts Medical School Faculty Publications by an authorized administrator of eScholarship@UMMS. For 











.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.




.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/452284doi: bioRxiv preprint first posted online Nov. 5, 2018; 
	 3	
Introduction		Hepatitis	C	(HCV)	infection	causes	inflammation	of	the	liver	and	can	lead	to	cirrhosis	and	liver	cancer	if	not	treated	effectively.	HCV	NS3/4A	protease	inhibitors	(PIs)	were	the	first	class	of	direct-acting	anti-virals	(DAAs)	approved	by	the	FDA	to	be	used	in	combination	with	peginterferon-alfa	and	ribavirin.	These	PIs	included	the	covalent,	acyclic	inhibitors	(telaprevir	(Perni,	Almquist	et	al.	2006,	Kwong,	Kauffman	et	al.	2011),	boceprevir	(Malcolm,	Liu	et	al.	2006))	and	a	non-covalent,	macrocyclic	inhibitor	(simeprevir	(Raboisson,	de	Kock	et	al.	2008,	Rosenquist,	Samuelsson	et	al.	2014).	Subsequently,	macrocyclic	PIs	have	been	developed	as	second-generation	DAAs,	including	danoprevir,	grazoprevir,	and	recently	FDA-approved	glecaprevir.			PIs	target	the	virally	encoded	serine	protease	NS3/4A.	NS3	is	a	631	amino-acid	bifunctional	protein,	with	a	serine	protease	domain	in	the	N-terminus	followed	by	an	NTPase/RNA	helicase	domain.	The	crosstalk	between	the	two	domains	has	been	previously	reported	(Frick,	Rypma	et	al.	2004,	Beran	and	Pyle	2008,	Beran,	Lindenbach	et	al.	2009,	Aydin,	Mukherjee	et	al.	2013),	but	domains	fold	into	active	proteins	independently.	NS3/4A	protease	domain,	a	chymotrypsin-like	fold	with	two	β-barrel	domains,	has	a	catalytic	triad	(H57,	D81,	S139)	located	in	a	cleft	separating	the	two	barrels.	NS4A,	a	54-amino	acid	peptide,	is	required	as	a	cofactor	for	optimal	proteolytic	activity.	The	central	11	amino	acids	of	the	cofactor	inserts	as	a	β-strand	to	the	N-terminal	β-barrel	of	NS3	to	form	the	active	enzyme	(Yao,	Reichert	et	al.	1999).			
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While	PIs	offer	a	subpopulation	of	patients	improved	sustained	virologic	response	and	the	potential	for	shorter	therapy	duration	(Jacobson,	McHutchison	et	al.	2011,	Poordad,	McCone	et	al.	2011,	Sherman,	Flamm	et	al.	2011,	Gane,	Pockros	et	al.	2012),	the	efficacy	of	approved	PIs	is	challenged	by	drug	resistance	(Halfon	and	Locarnini	2011,	Halfon	and	Sarrazin	2012,	Svarovskaia,	Martin	et	al.	2012,	Vermehren	and	Sarrazin	2012,	Welsch	and	Zeuzem	2012).	Mutations	arise	in	the	NS3/4A	protease	depending	on	the	therapeutic	regime;	A156	mutates	in	response	to	treatment	with	linear	ketoamide	protease	inhibitors	(Kieffer,	Sarrazin	et	al.	2007,	Sarrazin,	Kieffer	et	al.	2007,	Susser,	Welsch	et	al.	2009,	Halfon	and	Sarrazin	2012,	Svarovskaia,	Martin	et	al.	2012,	Vermehren	and	Sarrazin	2012,	Welsch	and	Zeuzem	2012)	while	macrocyclic	PIs	mainly	select	for	D168A	and	R155K	variants	(Manns,	Reesink	et	al.	2011,	Manns,	Bourliere	et	al.	2011,	Lim,	Qin	et	al.	2012).	Mutations	at	V36,	T54,	V36/R155	were	initially	reported	to	be	associated	with	resistance	to	ketoamide	inhibitors	(Kieffer,	Sarrazin	et	al.	2007,	Sarrazin,	Kieffer	et	al.	2007,	Susser,	Welsch	et	al.	2009).	V36M/R155K	mutations	were	observed	in	long-term	follow-up	of	patients	receiving	boceprevir	(Howe,	Long	et	al.	2015).	An	interferon-free	mericitabine/danoprevir	combination	therapy	resulted	in	a	confirmed	viral	breakthrough	in	21%	of	patients	(Gane,	Pockros	et	al.	2012)	and	these	patients	had	danoprevir-resistant	variants,	including	V36M/R155K.	Although	the	newer	PIs	have	improved	potency	and	cure	rates	in	combination	therapy,	dual	and	triple	mutant	variants	including	those	with	V36M	mutations	still	emerge	in	patients	failing	therapy	(Sorbo,	Cento	et	al.	2018)			We	have	previously	elucidated	the	structural	basis	of	resistance	due	to	the	active	site	mutation	R155K	by	crystal	structures	(Romano,	Ali	et	al.	2010,	Romano,	Ali	et	al.	2012).	
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R155	participates	in	an	electrostatic	network	of	interactions	along	the	substrate-binding	surface,	which	involves	residues	D81-R155-D168-R123.	This	strong	electrostatic	network	is	associated	with	tighter	substrate	binding	(Romano,	Laine	et	al.	2011),	therefore	is	critical	in	stabilization	of	the	bound	ligands.	In	fact,	most	early	inhibitors,	particularly	the	compounds	with	aromatic	P2	moieties,	pack	against	R155.	Our	crystal	structures	(Romano,	Ali	et	al.	2010,	Romano,	Ali	et	al.	2012,	Soumana,	Ali	et	al.	2014)	showed	that	the	R155K	mutation	disrupts	this	network	by	eliminating	one	of	the	two	hydrogen	bonds	of	R155.	As	a	result,	the	altered	charge	distribution	along	the	binding	surface	affects	the	P2	cyclopentylproline	and	P4	cyclohexylalanine	moieties	of	telaprevir	whereas	danoprevir	loses	a	favorable	cation-π	interaction	at	the	P2	isoindoline	(Romano,	Ali	et	al.	2012).	MD	simulations	based	on	these	crystal	structures	suggest	that	the	destruction	of	the	salt	bridge	between	168	and	155	may	cause	additional	conformational	changes	in	the	binding	pocket	(Pan,	Xue	et	al.	2012).		Unlike	R155K,	the	molecular	mechanism	of	resistance	for	V36M	mutation	is	unknown.	V36M	is	a	mutation	distal	to	the	active	site,	located	on	A1	strand,	>	13	Å	away	from	the	catalytic	histidine	(H57)	and	15	Å	from	R155	(Figure	1).	In	the	absence	of	crystal	structures,	molecular	modeling	led	to	the	hypothesis	that	the	distal	mutations	at	V36	and	T54	can	impair	interaction	with	telaprevir’s	cyclopropyl	group	(Welsch,	Domingues	et	al.	2008).	However,	no	experimental	data	exists	on	the	structural	changes	due	to	V36M	and	how	the	effects	of	this	distal	mutation	may	affect	PI	binding	at	the	active	site.	We	have	previously	developed	the	“network	hypothesis”	postulating	that	the	effect	of	distal	mutations	in	HIV-1	protease	are	propagated	to	the	active	site	through	a	network	of	intra-
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the	P2	groups	of	telaprevir	and	boceprevir	are	smaller	and	relatively	distant	to	the	155	sidechain.	The	R155K	mutation	disrupts	the	favorable	cation-π	stacking	and	causes	a	shift	in	the	danoprevir	P2	moiety	in	the	crystal	structures	of	both	the	single	and	double	mutant	complexes	(Figure	2	and	3A).	These	changes	have	been	described	as	the	mechanism	underlying	resistance	of	R155K	protease	to	danoprevir	(Romano,	Ali	et	al.	2012).	In	addition	to	these	structural	changes,	our	MD	simulations	here	reveal	that	the	interactions	of	danoprevir’s	P2	moiety	with	the	protease	are	destabilized	in	both	protease	variants,	with	a	considerably	enhanced	conformational	flexibility	of	the	bound	inhibitor	(Figure	3B).	This	enhanced	conformational	flexibility	causes	loss	of	favorable	interactions	even	more	than	those	observed	in	the	crystal	structures,	including	with	the	catalytic	residues	D81	and	H57	(Figure	4	versus	S1).	The	P2	moiety	samples	alternate	conformations	different	than	that	in	the	starting	crystal	structure	or	the	WT	complex	during	the	simulations	and	loses	more	than	6	kcal/mol	in	van	der	Waals	interactions	with	the	protease,	mainly	with	residues	155–157	(Figure	5).	In	both	single	and	double	mutant	variants,	danoprevir	also	loses	favorable	packing	of	the	P1'	moiety	with	F43	on	the	B1	strand	(Figure	5),	which	interfaces	both	the	active	site	and	A1	strand	containing	the	site	of	distal	mutation.	In	the	R155K/V36M	protease	complex,	danoprevir	forms	new	interactions	with	V158,	S159,	and	T160	not	present	in	WT	and	R155K	variants	(Figure	5).	Previously	we	found	these	residues	form	more	favorable	interactions	with	the	substrates	than	inhibitors	(Ozen,	Sherman	et	al.	2013).		Thus,	while	the	loss	of	van	der	Waals	interactions	in	the	danoprevir	crystal	structures	are	less	pronounced	and	comparable	for	the	single	and	double	mutant	variants,	the	destabilization	and	further	loss	of	P2	interactions	revealed	in	MD	simulations	correlate	with	the	high	fold-change	in	potency	(Table	1).	
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for	the	most	part	in	crystal	structures.	However	in	MD	simulations,	because	of	the	structural	rearrangement	in	the	binding	site	caused	by	V36M,	the	likelihood	of	a	hydrogen	bond	with	the	backbone	oxygen	decreases	~20%	for	telaprevir	and		~10%	for	boceprevir	(Table	S2).	The	most	striking	difference	between	the	crystal	structures	and	MD	simulations	is	that	both	telaprevir	and	danoprevir	lose	a	hydrogen	bond	with	the	catalytic	H57,	which	is	observed	~60%	of	the	time	between	boceprevir	and	WT	or	R155K	protease,	but	drops	to	34%	in	R155K/V36M	complex.	In	contrast,	hydrogen	bonds	with	R/K155	and	A157	(on	the	E2	strand)	are	preserved	in	the	MD	simulations,	suggesting	that	these	bonds	are	key	contributors	to	inhibitor	binding.	Hence,	drug	resistance	mutations	modulate	the	relative	stability	of	certain	inter-molecular	hydrogen	bonds	in	the	conformational	ensembles	sampled	in	the	MD	simulations	while	the	hydrogen	bonds	that	are	likely	indispensable	for	binding	remain	stable	across	crystal	structures	and	throughout	the	simulations	of	mutant	complexes.			The	electrostatic	network	at	the	binding	site	of	NS3/4A,	involving	residues	H57–R155–D168–R123,	is	important	for	substrate	recognition	and	inhibitor	binding	(Romano,	Laine	et	al.	2011,	Ali,	Aydin	et	al.	2013).	Disruption	of	this	network	can	arise	as	a	mechanism	of	resistance	by	weakening	inhibitor	binding.	Therefore,	sensitivity	of	the	salt	bridges	in	this	network	to	resistance	mutations	was	assessed	(Table	2).	R155	can	make	two	salt	bridges,	one	with	D81	and	the	other	with	D168	in	all	PI-bound	structures.	In	the	wild-type	protease	simulations,	R155–D168	salt	bridge	is	more	stable	than	the	R155–D81	salt	bridge,	consistent	with	the	distances	observed	in	the	crystal	structures	(6.4	Å	for	D81–R155	and	4.8	Å	for	R155–D168).	While	danoprevir	binding	further	stabilizes	R155–D168,	the	linear	
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Backbone	structural	changes	in	the	crystal	structures	were	assessed	by	computing	the	differences	in	the	internal	Cα-Cα	distances	between	the	resistant	and	wild-type	variants	bound	to	each	inhibitor	(Figure	7).	This	analysis	enables	determining	the	overall	conformational	perturbation	in	the	protein	structure	due	to	resistance	mutations	without	any	possible	superposition	bias	(see	Materials	and	Methods).			When	the	single	R155K	mutation	is	introduced	to	the	protease,	the	backbone	conformation	is	the	most	affected	in	the	macrocyclic	danprevir-bound	structure.	Introducing	V36M	mutation	to	the	R155K	variant	further	alters	the	backbone	conformation	relative	to	wild-type	complex.	Backbone	of	danoprevir-bound	protease,	which	has	a	~300-fold	reduction	in	inhibitory	activity	due	to	R155K/V36M,	is	altered	more	than	the	backbone	of	linear	telaprevir-	and	boceprevir-bound	protease	with	a	per-residue	average	difference	of	0.14	Å	(for	the	linear	inhibitors:	0.08	Å	for	telaprevir,	0.09	Å	for	boceprevir).	The	V36M	distal	mutation	shifts	the	danoprevir-bound	protease	backbone	both	at	the	binding	site	and	distal	regions	of	the	structure	(Figure	7).	Significant	binding	site	changes	include	the	loop	connecting	the	E2-F2	strands	and	the	α2	helix,	while	subtle	changes	are	observed	at	α1	helix	that	includes	the	catalytic	H57.	Distal	regions	with	substantial	backbone	perturbations	correspond	to	the	loop	connecting	the	β-strands	A1	(residue	36	is	located	on	A1)	and	B1,	the	α0	N-terminal	region,	and	the	α3	C-terminal	region.	Most	of	these	regions	are	also	flexible	and	exhibit	high	fluctuations	in	the	MD	simulations	(see	below	and	Figure	8).	Correspondence	between	the	crystallographic	changes	in	the	distance-difference	maps	and	the	relative	flexibility	in	MD	simulations	suggests	that	the	resistance	mutations	mainly	perturb	the	backbone	conformation	of	relatively	flexible	regions.		
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	In	addition	to	structural	changes	in	the	inhibitor-bound	state,	resistance	mutations	can	affect	the	conformational	dynamics	of	the	bound	and	unbound	states	(Cai,	Yilmaz	et	al.	2012).	Overall,	the	local	backbone	fluctuations	in	apo	versus	inhibitor-bound	complexes	of	wild	type	NS3/4A	protease	are	comparable	(Figure	8).	The	core	of	the	protein	comprised	mostly	of	beta	strands	is	highly	stable	in	all	simulations,	also	supported	by	the	stable	secondary	structures	over	the	trajectories.	Regions	with	changes	in	flexibility	mainly	correspond	to	loops	and	helices	(with	higher	RMSF	values	in	Figure	8).	The	fluctuations	of	the	short	α1	helix,	which	includes	the	catalytic	H57,	were	suppressed	when	telaprevir	or	danoprevir	binds	but	stays	apo-like	with	boceprevir	binding.	Another	region	that	is	in	close	proximity	to	the	binding	site,	corresponding	to	residues	130–137	and	including	helix	α2,	lost	flexibility	when	any	of	the	three	inhibitors	binds	(Figure	8),	consistent	with	earlier	simulation	results	(Zhu	and	Briggs	2011).	In	this	segment	of	NS3/4A,	I132,	L135,	K136,	and	G137	and	to	an	extent	S138	make	favorable	vdW	interactions	with	the	inhibitor	while	the	backbone	amide	of	G137	hydrogen	bonds	to	the	inhibitors.	Interestingly,	allosteric	inhibitors	of	NS2B/NS3	(Yildiz,	Ghosh	et	al.	2013),	another	trypsin-like	serine	protease	from	dengue	virus,	bind	a	region	of	the	enzyme	that	is	topologically	similar	to	the	130–137	segment	of	HCV	NS3/4A.	Structural	ordering	achieved	by	tight,	favorable	interactions	with	the	inhibitor	implies	a	role	of	this	3-10	helix	in	stabilizing	the	active	site.		We	next	analyzed	changes	in	backbone	fluctuations	due	to	resistance	mutations	(Figure	9).	Relatively	restrained	residues	in	the	wild-type	protease,	bound	or	unbound,	are	not	majorly	affected	by	the	resistance	mutations.	The	most	striking	change	in	atomic	
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strands	and	the	α2	helix	are	closer	to	each	other	suggests	a	slight	shrinking	in	the	binding	site	across	the	B1–E2	strands	direction.				Structural	and	dynamic	reorganization	in	the	binding	site	involving	the	α2	helix	and	B1	and	E2	strands	also	impacted	the	catalytic	triad	(Figure	10B).	In	the	apo	protease,	S139	was	pulled	away	from	H57	and	D81	with	the	V36M	mutation.	In	telaprevir	and	danoprevir	complexes,	R155K	mutation	caused	H57	and	D81	Cα	atoms	to	get	farther	away	from	each	other,	which	was	further	aggravated	by	V36M	in	danoprevir-bound	protease.	When	farther	apart,	the	sidechains	of	these	two	catalytic	residues	are	not	oriented	properly	for	strong	salt	bridging	(Table	2).	In	contrast,	the	distances	and	the	H57-D81	salt	bridge	were	conserved	in	complexes	of	boceprevir,	which	is	the	least	susceptible	of	the	three	inhibitors	to	R155K/V36M	resistance	mutations	(Table	1).			Additional	residue	pairs	across	the	protease	indicate	changes	in	the	conformational	dynamics	due	to	the	resistance	mutations.	The	H57-K136	distance	decreased	in	the	unbound	variants	of	R155K	and	R155K/V36M,	with	a	bimodal	distribution	in	R155K/V36M	(Figure	S4).	Since	K136	makes	key	interactions	with	the	natural	substrates,	one	would	expect	that	a	change	in	the	relative	orientation	of	K136	with	respect	to	the	catalytic	H57	could	alter	the	balance	in	the	molecular	recognition	events	in	favor	of	substrate	recognition	versus	inhibitor	binding.	The	loops	connecting	A1-B1	and	E2-F2	strands,	which	can	be	thought	of	as	“pseudo-flaps”	in	analogy	to	HIV-1	protease,	were	also	closer	to	each	other	in	the	apo	and	danoprevir-bound	proteases	while	the	width	of	the	distribution	changed	in	telaprevir-bound	state	(Figure	S3).	
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macrocyclic	danoprevir;	the	fold-change	in	Ki	due	to	V36M	was	9	and	4	for	telaprevir	and	boceprevir,	respectively	and	2	for	danoprevir	in	the	R155K	background.	However,	as	danoprevir	is	highly	susceptible	to	R155K	(158-fold	change	relative	to	WT),	the	double	mutant	had	almost	300	times	higher	inhibition	constant	than	the	WT	protease.		Why	the	V36M	mutation	distal	from	the	active	site	is	selected	in	combination	with	R155K	and	how	this	mutation	is	able	to	impact	inhibitor	susceptibility	is	not	entirely	evident	from	the	crystal	structures	alone.	The	impact	of	the	distal	V36M	mutation	on	the	crystal	structures	is	subtle,	with	little	change	in	the	inhibitor	binding	mode,	intermolecular	hydrogen	bonds	or	salt	bridges.	However,	rather	than	local	changes	at	the	binding	site,	V36M	alters	the	overall	protein	conformation	and	dynamics	around	the	active	site	via	changes	in	interactions	with	F43	on	B1	strand	(Figures	7,	10	and	S2).	Our	results	suggest	that	the	impact	of	V36M	mutation	is	propagated	to	the	binding	site	through	B1	β-strand	since	V36	is	located	on	the	A1	β-strand,	right	next	to	B1	strand.	The	fact	that	F43,	on	B1	β-strand,	is	also	a	resistance	mutation	site	supports	this	hypothesis.	The	result	of	this	distal	modulation	is	an	effective	decrease	in	the	size	of	the	active	site.	Because	the	NS3/4A	inhibitors	typically	protrude	beyond	the	dynamic	substrate	envelope	(Ozen,	Sherman	et	al.	2013),	this	shrinking	is	expected	to	impair	inhibitor	binding	more	than	substrate	recognition,	and	contribute	to	drug	resistance.	These	results	are	reminiscent	and	consistent	with	the	“network	hypothesis”	and	the	decrease	in	active	site	size	we	observed	previously	with	HIV-1	protease	(Ragland,	Nalivaika	et	al.	2014).		
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The	V36M	mutation	may	also	interfere	with	the	binding	of	the	cofactor	NS4A,	which	aids	in	the	proper	folding	of	NS3.	Substitution	of	a	valine	with	a	larger	sidechain,	methionine,	alters	the	local	packing.	Since	the	A1	strand	containing	V36	is	in	direct	contact	with	NS4A	in	structure,	a	mutation	in	A1	may	as	well	affect	the	interactions	with	NS4A.	A	hindrance	in	cofactor	binding	would	also	interfere	with	substrate	processing	efficiency,	which	may	be	the	reason	for	the	reduced	base-level	replicative	capacity	of	V36M	and	R155K/V36M	variants	of	genotype	1b	viruses	in	the	absence	of	drugs	(44%	and	76%	relative	to	wild-type)	(He,	King	et	al.	2008).		The	MD	simulations	here	provided	additional	insights	also	into	the	mechanism	of	resistance	due	to	R155K	mutation,	which	was	previously	revealed	from	crystal	structures	(Romano,	Ali	et	al.	2010,	Romano,	Ali	et	al.	2012).	The	destabilization	of	danoprevir’s	P2	isoindoline	in	the	presence	of	R155K	both	in	the	crystal	structures	and	MD	simulations	is	consistent	with	earlier	simulation	results	of	Pan	et	al	(Pan,	Xue	et	al.	2012),	indicating	that	the	severe	destabilization	of	P2	is	not	a	crystallization	or	force-field	dependent	artifact.	In	fact,	the	P2	moiety	samples	diverse	conformations	distinct	from	the	one	observed	in	the	crystal	structure	(Figure	3),	with	substantial	losses	in	vdW	interactions	with	the	active	site	protease	residues.		While	the	substrate	envelope	effectively	explains	the	molecular	mechanism	of	resistance	to	most	active	site	mutations,	understanding	the	effect	of	mutations	distal	to	the	binding	site	on	inhibitor	susceptibility	is	more	challenging.	Earlier	studies	on	HIV-1	protease	showed	that	drug	resistance	can	be	conferred	not	only	via	changes	in	direct	interactions	with	the	
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cutoff	of	0.3	Å.	This	step	allows	hydrogen	atoms	to	be	freely	minimized,	while	allowing	heavy-atom	movement	to	relax	strained	bonds,	angles,	and	clashes.			Desmond(Bowers,	Chow	et	al.	2006)	with	OPLS2005	force	field	(Jorgensen,	Chandrasekhar	et	al.	1983,	Shivakumar,	Williams	et	al.	2010)	was	used	in	all	simulations.	The	prepared	systems	were	solvated	in	an	orthorhombic	solvent	box	with	the	SPC	water	model	extending	10	Å	beyond	the	protein	in	all	directions	using	the	System	Builder	utility.	The	overall	charge	of	the	system	was	neutralized	by	adding	the	appropriate	number	of	counterions	(Na+	or	Cl−).			Each	system	was	relaxed	using	a	protocol	consisting	of	an	initial	minimization	restraining	the	solute	heavy	atoms	with	a	force	constant	of	1000	kcal	mol-1	Å-2	for	10	steps	with	steepest	descent	and	with	LBFSG	method	up	to	2000	total	steps	with	a	convergence	criterion	of	50.0	kcal	mol-1	Å-2.	The	system	was	further	minimized	by	restraining	only	the	backbone	and	allowing	the	free	motion	of	the	sidechains.	At	this	stage,	the	restraint	on	the	backbone	was	gradually	reduced	from	1000	to	1.0	kcal	mol-1	Å-2	with	5000	steps	(250	steepest	descent	plus	4750	LBFSG)	for	each	value	of	force	constant	(1000,	500,	250,	100,	50,	10,	1.0	kcal	mol-1	Å-2)	and	finally	an	unrestrained	energy	minimization	was	performed.			After	energy	minimization,	each	system	was	equilibrated	by	running	a	series	of	short	MD	steps.	First,	a	10	ps	MD	simulation	at	10	K	was	performed	with	a	50	kcal	mol-1	Å-2	restraint	on	solute	heavy	atoms	and	using	Berendsen	thermostat	in	the	NVT	ensemble.	MD	steps	were	integrated	using	a	two	time-step	algorithm,	with	1	fs	steps	for	bonded	and	
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while	backbone	structural	changes	occur	mostly	around	the	binding	site	and	in	the	loop	regions.		
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Table	1.		Drug	susceptibilities	against	wild-type	and	resistant	HCV	clones	and	inhibitory	activities	against	NS3/4A	proteases.	
Full-length	NS3/4A	Enzyme	-	Ki	(nM)a		 WT	 R155K	 R155K/V36M	
Telaprevir	 40.9	±	3.7	 824.0	±	75.1	(20)	 >10,000	(>244)	
Boceprevir	 34.7	±	2.9	 390.8	±	43.0	(11)	 1018.0	±	192.3	(29)	
Danoprevir	 1.2	±	0.1	 132.0	±	18.0	(111)	 292.9	±	38.6	(246)	
Protease	domain	Ki	(nM)a			
	 WT	 R155K	 R155K/V36M	
Telaprevir	 33.3	±	4.0	 803.7	±	89.9	(24)	 7342	±	1281	(220)	
Boceprevir	 35.4	±	3.3	 236.7	±	44.3	(7)	 1097.0	±	120.4	(31)	
Danoprevir	 1.0	±	0.1	 157.9	±	20.5	(158)	 295.5	±	34.3	(295)	
Replicon	IC50	(nM)a			 WT	 R155K	 R155K/V36M	
Telaprevir	 1349	 4740	(3.5)	 15759	(12)	
Boceprevir	 971	 2788	(3)	 3941	(4)	
Danoprevir	 0.24	 >100	(>416)	 >100	(>416)	aNumbers	in	parentheses	reflect	fold-change	relative	to	wild-type;	>	indicates	IC50	and	Ki	values	higher	than	the	maximum	drug	concentration	tested	in	the	assay.		
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